T7 010
Alternative Names: T7-010Latest Information Update: 22 Aug 2025
At a glance
- Originator T7 Therapeutics
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 28 Jul 2025 T7 Therapeutics plans a phase I trial for autoimmune disorders (In volunteers) in Hungary in July 2025 (EUCT2024-518440-20-00)
- 27 May 2025 Preclinical trials in Autoimmune disorders in USA (unspecified route) before May 2025